Abstract: ABSTRACT BACKGROUND&OBJECTIVE:. To compare the efficacy and toxicities of gemcitabine combined vinorelbine ( GN) ×8 regimen and gemcitabine combined vinorelbine ( GN) ×4 follow oral N ×4 regimen as chemotherapy for anthracycline- and taxane- resistant metastatic breast cancer(MBC) Patients and Methods:. 61 patients were treated by GN or GN×4— N regimen. Overall response rate( ORR) and 1- year survival of two groups were assessed after treatment RESULTS：CR was 6. 5% ( 2 /31) and PR was 29.0% (9 /31) in GN group. 2 patients ( 6.9% ) had a complete response( CR) and 8 patients ( 27.6% ) had a partial response( PR) in GN×4—N group. No statistically significant difference was observed in terms of ORR( 35.5% vs. 33.3%. , P =0.925) , or 1- year survival rate ( 67.7% vs. 65.5%, P =0.576) of the two groups. No patients died in correlated with the two regimens. Myelosuppression and gastrointestinaltract reaction were the most common toxicities. CONCLUSIONS:. GN and GN×4—N regimens are both well effective for patients with anthracycline- and taxane- resistant MBC. Drug- related toxicities are tolerable. Two regimens can be considered as salvage regimens for those patients.

摘要： ［摘要］ 目的 比较 GN（吉西他滨/长春瑞滨）4 疗程后序贯 GN×4（GN×8 组）或序贯口服 N×4 方案（GN×4?N 组）治疗对晚期乳腺癌（MBC）的疗效及不良反应。方法 选取2014 年1 月至2015 年12 月确诊的晚期乳腺癌患者 61 人，采用 GN×4 疗程后序贯 GN×4 或序贯口服N×4 方案化疗，比较患者的总有效率（ORR）及 1 年生存率。结果 GN×8 组 ORR 为 35.5%（11/31），其中 CR 6.5%（2/31），PR 29%（9/31）；GN×4?N 组 ORR 为 33.3%（10/30），其中 CR 6.7%（2/30），PR 26.7%（8/30），两组 ORR 差异无统计学意义（P=0.925），GN×8 组 1 年生存率为 67.7%；GN×4?N 组 1 年生存率为65.5%，两组1 年生存率差异无统计学意义（P=0.576）。两组均无化疗相关死亡病例，主要不良反应为骨髓抑制及胃肠道反应。结论 GN4 疗程后序贯GN×4 或序贯口服N×4 方案对于MBC 均有较好的有效率，不良反应均可耐受。但从药物经济学及患者的生活质量上讲，GN×4?N 更符合晚期治疗患者“低毒高效、服用方便”的原则。

关键词: 口服长春瑞滨, 吉西他滨, 化疗, 乳腺癌